With no further treatment, the 1996 ten-month follow-up data (n=92) from a high drug pollen period in Oregon, Washington and Idaho together showed a greater reduction in the active group (n=43) than the placebo group (n=49) on the test primary endpoint, defined as a combination of symptom and rescue medication scores.8 Patients gave blood serum samples prior to the treatment in 1995 and one year later in 1996. They were immunoassayed for specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley detoxifiers Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. For the seasonal allergens reported, the active group (n=27) had on average a greater reduction in IgE than the placebo group (n=34) for 13 out of 16 allergens.8

Feeling drug fine in general, allergy symptoms improved. C. T. Have been doing a lot better. Lisa L. So far, so good. Andy G. Felt congested, but improved. Richard R. Feeling test and detoxifiers fine. No problems. Roland H. Feel OK as far as allergies. Angel P. I felt relief after the treatment, and still feeling better. A. V. I feel OK, but have a little congestion. Carlin R. Feel better than before. Art P. Feel good - continue with sinusitis Bob M. Feeling moderate. Gustavo M. Much better. Alejandro M. What Patients Said After More Than Two Months All my symptoms seem to have gone. Margareth Z. For the first time after taking the treatment, I felt like my life was my own. After 20 years I was able to go out in traffic and high winds with little or no bad effects. I could even tolerate gas lawn mowers. I was able to walk around without huffing drug and puffing. Pain in throat and lungs disappeared. Getting air in lungs.

All test and detoxifiers of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo drug controls reported either no change or a worsening of symptoms. Wilcoxon-Rank test of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged detoxifiers the safety of the treatment. The panel seemed drug to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative test drop in symptoms was demonstrated. detoxifiers In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was drug repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite test and detoxifiers challenge.6

©2003 www.female-prenatal-supplements.com All rights reserved.